Download PDF
Horm Metab Res 2011; 43(11): 737-742
DOI: 10.1055/s-0031-1291177
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

Cardiac Specific Effects of Thyroid Hormone Analogues

S. Danzi
1   Department of Medicine, North Shore University Hospital and Feinstein Institute for Medical Research, Manhasset, New York, USA
,
I. Klein
1   Department of Medicine, North Shore University Hospital and Feinstein Institute for Medical Research, Manhasset, New York, USA
› Author Affiliations
Further Information

Publication History

received 20 June 2011

accepted 07 September 2011

Publication Date:
18 October 2011 (online)

Also available at
    Permissions and Reprints

Abstract

There is significant interest in development of thyroid hormone analogues to harness specific properties as therapeutic agents for a variety of clinical indications including obesity, hypercholesterolemia, heart failure, and thyrotoxicosis. To date, most analogues have been designed to target liver specific effects, which can promote weight loss and lipid lowering through either tissue specific uptake or thyroid hormone receptor (TR) β isoform selectivity at the same time minimizing the unwanted cardiac and bone effects. We have developed a molecular biomarker assay to study the induction of the transcription of the cardiac specific α-myosin heavy chain (MHC) gene as a more sensitive and specific measure of thyroid hormone action on cardiac myocytes. We tested 5 TRβ and 1 TRα selective agonists as well as 2 putative TR antagonists in our α-MHC hnRNA assay. Using reverse transcription and polymerase chain reaction, we measured the induction of the α-MHC primary transcript in response to administration of drug. The TRα and only 2 of the TRβ agonists were highly active, when compared to the effect of T3, at the level of the cardiac myocyte. In addition, our data suggests that the reason that the antagonist NH-3 is not able to block the T3-mediated induction of α-MHC is that it does not get transported into the cardiac myocyte. Our data suggest that this assay will be useful in preclinical studies of the potential cardiac specific effects of thyroid hormone analogues and that predictions of function based on structure are not necessarily accurate or complete.

Key words

analogue - heart - T3 - T4 - triiodothyronine
 

  • References

  • 1 Morkin E, Ladenson P, Goldman S, Adamson C. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 2004; 37: 1137-1146
    PubMedGoogle Scholar
  • 2 Brenta G, Danzi S, Klein I. Potential Therapeutic Applications of Thyroid Hormone Analogs. Nat Clin Pract Endocrinol Metab 2007; 3: 632-640
    CrossrefPubMedGoogle Scholar
  • 3 Ribeiro MO. Effects of thyroid hormone analogs on lipid metabolism and thermogenesis. Thyroid 2008; 18: 197-203
    CrossrefPubMedGoogle Scholar
  • 4 Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007; 104: 15490-15495
    CrossrefPubMedGoogle Scholar
  • 5 Castillo M, Freitas BCG, Rosene ML, Drigo RA, Grozovsky R, Maciel RMB, Patti ME, Ribeiro MO, Bianco AC. Impaired Metabolic Effects of a Thyroid Hormone Receptor Beta-Selective Agonist in a Mouse Model of Diet-Induced Obesity. Thyroid 2010; 20: 545-554
    CrossrefPubMedGoogle Scholar
  • 6 Klein I, Danzi S. Thyroid Disease and the Heart. Circulation 2007; 116: 1725-1735
    CrossrefPubMedGoogle Scholar
  • 7 Sadow PM, Chassande O, Koo EK, Gauthier K, Samarut J, Xu J, O’Malley BW, Weiss RE. Regulation of expression of thyroid hormone receptor isoforms and coactivators in liver and heart by thyroid hormone. Mol Cell Endocrinol 2003; 203: 65-75
    CrossrefPubMedGoogle Scholar
  • 8 Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Treatment of Dyslipidemia with the Thyroid Hormone Analog Eprotirome in Statin-Treated Patients. New Engl J Med 2010; 362: 906-916
    CrossrefPubMedGoogle Scholar
  • 9 Everts ME, Verhoeven FA, Bezstarosti K, Moerings E, Hennemann G, Visser TJ, Lamers JMJ. Uptake of Thyroid Hormones in Neonatal Rat Cardiac Myocytes. Endocrinology 1996; 137: 4235-4242
    CrossrefPubMedGoogle Scholar
  • 10 Danzi S, Ojamaa K, Klein I. Triiodothyronine-Mediated Myosin Heavy Chain Gene Transcription in the Heart. Am J Physiol Heart Circ Physiol 2003; 284: H2255-H2262
    PubMedGoogle Scholar
  • 11 Balkman C, Ojamaa K, Klein I. Time course of the effects of thyroid hormone on cardiac gene expression. Endocrinology 1992; 130: 2001-2006
    CrossrefPubMedGoogle Scholar
  • 12 Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC, Scanlan TS. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 1998; 5: 299-306
    CrossrefPubMedGoogle Scholar
  • 13 Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan TS, Dillmann WH. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000; 141: 3057-3064
    CrossrefPubMedGoogle Scholar
  • 14 Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen NH, Baxter JD, Scanlan TS. Effects of the thyroid hormone receptor GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3’-triiodo-L-thyronine. Endocrinology 2004; 145: 1656-1661
    PubMedGoogle Scholar
  • 15 Baxter JD, Webb P, Grover G, Scanlan TS. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 2004; 15: 154-157
    CrossrefPubMedGoogle Scholar
  • 16 Johansson L, Rudling M, Scanlan TS, Lundasen T, Webb P, Baxter J, Angelin B, Parini P. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 2005; 102: 10297-10302
    CrossrefPubMedGoogle Scholar
  • 17 Baxter JD, Dillmann WH, West BL, Huber R, Furlow JD, Fletterick RJ, Webb P, Apriletti JW, Scanlan TS. Selective modulation of thyroid hormone receptor action. J Steroid Biochem Mol Biol 2001; 76: 31-42
    CrossrefPubMedGoogle Scholar
  • 18 Lim W, Nguyen NH, Yang HY, Scanlan TS, Furlow JD. A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J Biol Chem 2002; 277: 35664-35670
    CrossrefPubMedGoogle Scholar
  • 19 Nguyen NH, Apriletti JW, Cunha Lima ST, Webb P, Baxter JD, Scanlan TS. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 2002; 45: 3310-3320
    CrossrefPubMedGoogle Scholar
  • 20 Grover GJ, Dunn C, Nguyen NH, Boulet J, Dong G, Domogauer J, Barbounis P, Scanlan TS. Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats. J Pharmacol Exp Ther 2007; 322: 385-390
    CrossrefPubMedGoogle Scholar
  • 21 Baxter JD, Goede P, Apriletti JW, West BL, Feng W, Mellstrom K, Fletterick RJ, Wagner RL, Kushner PJ, Ribeiro RC, Webb P, Scanlan TS, Nilsson S. Structure-Based Design and Synthesis of a Thyroid Hormone Receptor (TR) Antagonist. Endocrinology 2002; 143: 517-524
    CrossrefPubMedGoogle Scholar
  • 22 Schapira M, Raaka BM, Samuels HH, Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 2000; 97: 1008-1013
    CrossrefPubMedGoogle Scholar
  • 23 Borngraeber S, Budny MJ, Chiellini G, Cunha-Lima ST, Togashi M, Webb P, Baxter JD, Scanlan TS, Fletterick RJ. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci USA 2003; 100: 15358-15363
    CrossrefPubMedGoogle Scholar